| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
N4-Acetylcytidine does not have a well-defined pharmacological target, as it is an endogenous RNA modification rather than a drug molecule. It is a metabolite that plays roles in cell viability and development. The compound's formation is catalyzed by NAT10, and it is found in various RNA species. Its levels may be altered in inflammation-related diseases, making it a potential biomarker. However, it is not used as a therapeutic agent.
|
|---|---|
| ln Vitro |
N4-Acetylcytidine does not possess significant pharmacological activity as a pure compound in typical in vitro assays, as it is an endogenous metabolite and RNA modification. Studies may involve measuring its levels in biological samples as a biomarker. The compound is also used as a reference standard in analytical chemistry for the identification and quantification of modified nucleosides. It is not studied for specific biological activities.
|
| ln Vivo |
In vivo activity of N4-Acetylcytidine is related to its role as a modified RNA nucleoside and metabolite. It is involved in RNA metabolism and may play roles in cell viability and development. The compound's levels may be altered in inflammation-related diseases, making it a potential biomarker. However, comprehensive in vivo studies evaluating its pharmacokinetic properties, efficacy, and safety are limited.
|
| Enzyme Assay |
N4-Acetylcytidine is an endogenous metabolite and modified RNA nucleoside, not a drug candidate. It serves as a biomarker for inflammation-related diseases. In research, it is used as a reference standard in analytical chemistry for the identification and quantification of modified nucleosides. Its chemical properties are characterized using standard analytical methods such as HPLC and mass spectrometry.
|
| Cell Assay |
N4-Acetylcytidine is used as a reference standard in analytical chemistry and may be studied in cell-based assays to understand its role as an RNA modification. It is not typically used in pharmacological cellular assays. Research may focus on measuring its levels in cells or tissues as a biomarker for disease states.
|
| Animal Protocol |
N4-Acetylcytidine is an endogenous metabolite, not a drug candidate. It is not typically used in animal experiments for pharmacological purposes. Studies may involve measuring its levels in animal models of inflammation-related diseases as a biomarker.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to N4-Acetylcytidine as it is an endogenous metabolite rather than a drug candidate. It is a naturally occurring modified nucleoside found in RNA and is metabolized as part of normal cellular processes. Its levels in biological fluids may reflect disease states.
|
| Toxicity/Toxicokinetics |
N4-Acetylcytidine is an endogenous metabolite and is not considered toxic. It is a normal component of RNA and is involved in cellular processes. However, elevated levels may be associated with disease states. Standard safety precautions for handling laboratory chemicals apply.
|
| Additional Infomation |
N(4)-Acetylcytidine is a derivative of cytidine, in which one of the outer ring amino hydrogen atoms is replaced by an acetyl group. It is a metabolite. It belongs to the cytidine, acetamide, and secondary carboxamide classes. N4-Acetylcytidine has been reported in Saccharomyces cerevisiae, and relevant data are available for reference.
N4-Acetylcytidine is a research compound that has not entered clinical trials or received regulatory approval for therapeutic use. It is primarily used as a biomarker for the diagnosis of inflammation-related diseases and as a reference standard in analytical chemistry. The compound is a highly conserved modified RNA nucleoside whose formation is catalyzed by NAT10. It is also known as ac4C. |
| Molecular Formula |
C₁₁H₁₅N₃O₆
|
|---|---|
| Molecular Weight |
285.25
|
| Exact Mass |
285.096
|
| CAS # |
3768-18-1
|
| PubChem CID |
107461
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Melting Point |
199ºC (dec.)
|
| Index of Refraction |
1.699
|
| LogP |
-1.63
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
477
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]([H])([C@]1([H])N1C(N=C(C([H])=C1[H])N([H])C(C([H])([H])[H])=O)=O)O[H])O[H]
|
| InChi Key |
NIDVTARKFBZMOT-PEBGCTIMSA-N
|
| InChi Code |
InChI=1S/C11H15N3O6/c1-5(16)12-7-2-3-14(11(19)13-7)10-9(18)8(17)6(4-15)20-10/h2-3,6,8-10,15,17-18H,4H2,1H3,(H,12,13,16,19)/t6-,8-,9-,10-/m1/s1
|
| Chemical Name |
N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide
|
| Synonyms |
N4Acetylcytidine; N4 Acetylcytidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~87.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5057 mL | 17.5285 mL | 35.0570 mL | |
| 5 mM | 0.7011 mL | 3.5057 mL | 7.0114 mL | |
| 10 mM | 0.3506 mL | 1.7528 mL | 3.5057 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA